JUNS

Jupiter Neurosciences, Inc. is a clinical-stage research and development pharmaceutical company. The Company has developed a resveratrol platform product targeting the treatment of neuro-inflammation. Its product, JOTROL, has many potential indications of use for rare diseases, which primarily targets Mucopolysaccharidoses Type 1, Friedreich's Ataxia, and Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes (MELAS). In the larger disease areas, it primarily targets Parkinson’s Disease and Mild Cognitive Impairment/early Alzheimer’s disease. The Company has designated the different indications with project numbers, JNS101 - JNS115. JOTROL is a micellar non-aqueous solution of resveratrol delivered in a soft gel capsule. Each capsule includes 100mg of resveratrol. It has a worldwide license from Aquanova AG, the patent holder of micellar technologies, to develop, manufacture, distribute and sell JOTROL.

Wall Street analysts forecast JUNS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for JUNS is 25.00 USD with a low forecast of 25.00 USD and a high forecast of 25.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Jupiter Neurosciences Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

Jupiter Neurosciences Inc. EPS for the last quarter amounts to -0.07 USD, increased 250.00 % YoY.

Jupiter Neurosciences Inc (JUNS) has 4 emplpoyees as of December 15 2025.

Today JUNS has the market capitalization of 37.18M USD.